Medication info
Duotelmi Plus Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Duotelmi Plus Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›Strength being verifiedAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Hankook Hutech Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500398 · Approved 2025.02.25 · Insurance code 649106110

Summary

Main use
Treatment of hypertension and dyslipidemia, and prevention of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination and rosuvastatin as separate medicines, they may be switched to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, consider switching directly to the telmisartan/amlodipine combination as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Hankook Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, and prevention of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used to treat primary hypertension in patients whose blood pressure is not adequately controlled by the monotherapy of telmisartan and amlodipine. Additionally, rosuvastatin is prescribed, along with a dietary regimen, for various lipid disorders including hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia to lower serum cholesterol levels and delay the progression of atherosclerosis. Furthermore, rosuvastatin helps reduce the risk of myocardial infarction, stroke, and arterial revascularization in men over 50 and women over 60 with elevated high-sensitivity C-reactive protein and additional cardiovascular risk factors. Therefore, this medication is effectively used for the prevention and treatment of cardiovascular diseases in patients with combined hypertension and dyslipidemia.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination and rosuvastatin as separate medicines, they may be switched to this medicine (a combination product containing the same amount of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, consider switching directly to the telmisartan/amlodipine combination as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and neonate during pregnancy, and use should be discontinued immediately upon confirmation of pregnancy. Individuals with allergies to the components of this medication or similar drugs, as well as those with certain hereditary diseases or severe liver/kidney dysfunction, should not use this medication. Elderly patients or patients with low blood pressure, hyperkalemia, and liver impairment should exercise increased caution when using this medication, and should consult a physician immediately if muscle-related abnormal symptoms appear. This medication may cause serious muscle disorders such as myalgia, myopathy, and, rarely, rhabdomyolysis, so it is essential to inform medical staff promptly if muscle pain or weakness occurs. Since this medication may affect liver function, it is necessary to undergo routine liver function tests while taking it. Interactions with other medications may occur while taking this medication, so it is important to inform medical staff about any other medications being taken. Dizziness or drowsiness may occur when driving or operating machinery, so caution is advised. In case of overdose, symptoms such as hypotension, dizziness, and arrhythmia may occur, and immediate medical attention is required. Safety and efficacy in children have not been sufficiently confirmed, so it is not recommended for use in children. This medication must be stored out of reach of children and should not be transferred to another container.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatus hernia, infection, fungal infection, abscess, otitis media, palpitations, dependency edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, dizziness, sensory abnormalities, involuntary muscle contractions, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disorders, gout, hypercholesterolemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, nervous hyperexcitability, vascular edema, dermatitis, rash, eczema, pruritus, frequent urination, cystitis, cerebrovascular disease, visual disturbances, conjunctivitis, tinnitus, ear pain, headache, dizziness, weakness, cough, fatigue, asthenia, facial edema, lower limb edema, vascular edema, pruritus, hypersensitivity reaction, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, fainting, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, lumbar pain, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, vascular edema, edema, dizziness, orthostatic hypotension, lumbar pain, headache, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, burning sensation, malaise, rigidity, weight gain, weight loss, sexual dysfunction, insomnia, abnormal dreams, depersonalization, vasculitis, vascular edema, polymorphous erythema, rash, erythematous rash, papular rash, double vision, eye pain, tinnitus, ear pain, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, heart failure, irregular pulse, ectopic beats, skin depigmentation, dry skin, hair loss, dermatitis, muscle weakness, single contraction, impaired coordinated movement, hypertonia, cool and moist skin, apathy, anxiety, amnesia, gastritis, increased appetite, loose stools, rhinitis, urinary disorders, polyuria, abnormal olfactory perception, gustatory distortion, abnormal eye movement control, dry eyes, gynecomastia, jaundice, elevated liver enzyme levels, leukopenia, altered mental state, peeling dermatitis, Stevens-Johnson syndrome, phototoxic reaction, toxic epidermal necrolysis, polyneuropathy, amnesia, peripheral neuropathy, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, myasthenia gravis.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects it from light. Additionally, it is best to store the medication at room temperature, ideally between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.